Pharmacy Innovations: Drug Recall

Recall #D-0239-2023 · 12/22/2022

Class II: Risk

Recall Details

Recall Number: D-0239-2023
Classification: Class II
Product Type: Drug
Recalling Firm: Pharmacy Innovations
Status: Terminated
Date Initiated: 12/22/2022
Location: Erie, PA, United States
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: N/A

Reason for Recall

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Product Description

THIAMINE/RIBOFLA/NIACINAMI/DEXPANTH/PYRIDOX/HYDROXYCOBAL 25MG/25MG/25MG/25MG/25MG/20MG/ML (3ML VIAL) INJECTABLE THIAMINE/RIBOFLA/NIACINAMI/DEXPANTH/PYRIDOX/METHYLFOLATE/METHYLCOBAL 10MG/2.5MG/25MG/5MG/5MG/10MG/10MG/ML (1ML VIAL) INJECTABLE THIAMINE/RIBOFLAVIN/NIACINAMIDE/DEXPANTHENOL/PYRIDOXINE 50MG/1MG/100MG/3MG/2MG/ML (30ML VIAL) INJECTABLE, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.

Distribution Pattern

Nationwide in the USA

Other Recalls by Pharmacy Innovations

Class II: Risk 12/22/2022

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class II: Risk 12/22/2022

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class II: Risk 12/22/2022

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class II: Risk 12/22/2022

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.
Class II: Risk 12/22/2022

Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

View all recalls by Pharmacy Innovations →

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.